ST Bailing's Subsidiary Receives Clinical Trial Approval for Tangning Tongluo Cream

Stock News

2 hours ago

Guizhou Bailing Group Pharmaceutical Co.,Ltd. (002424.SZ) has announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.

The notice confirms that the clinical trial application for Tangning Tongluo Cream meets the relevant requirements for drug registration. Upon further refinement of the clinical trial protocol, approval has been granted to conduct trials for the treatment of diabetic foot ulcers.

This approval marks a significant milestone in the research and development pipeline for the Tangning Tongluo series, representing a key phased achievement. It facilitates the advancement of the company's "oral plus topical" treatment system for diabetic complications. The receipt of clinical trial approval for the cream is not expected to have a material impact on the company's current-period financial results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/news/1182838283"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182838283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182838283?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182838283","market":"other","top_or_hot":-1,"title":"ST Bailing's Subsidiary Receives Clinical Trial Approval for Tangning Tongluo Cream","media":"Stock News","content":"<p><b>Guizhou Bailing Group Pharmaceutical Co.,Ltd.</b> (002424.SZ) has announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.<br><br>The notice confirms that the clinical trial application for Tangning Tongluo Cream meets the relevant requirements for drug registration. Upon further refinement of the clinical trial protocol, approval has been granted to conduct trials for the treatment of diabetic foot ulcers.<br><br>This approval marks a significant milestone in the research and development pipeline for the Tangning Tongluo series, representing a key phased achievement. It facilitates the advancement of the company's \"oral plus topical\" treatment system for diabetic complications. The receipt of clinical trial approval for the cream is not expected to have a material impact on the company's current-period financial results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST Bailing's Subsidiary Receives Clinical Trial Approval for Tangning Tongluo Cream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST Bailing's Subsidiary Receives Clinical Trial Approval for Tangning Tongluo Cream\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-16 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Guizhou Bailing Group Pharmaceutical Co.,Ltd.</b> (002424.SZ) has announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.<br><br>The notice confirms that the clinical trial application for Tangning Tongluo Cream meets the relevant requirements for drug registration. Upon further refinement of the clinical trial protocol, approval has been granted to conduct trials for the treatment of diabetic foot ulcers.<br><br>This approval marks a significant milestone in the research and development pipeline for the Tangning Tongluo series, representing a key phased achievement. It facilitates the advancement of the company's \"oral plus topical\" treatment system for diabetic complications. The receipt of clinical trial approval for the cream is not expected to have a material impact on the company's current-period financial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDTX","symbol_name":"Corgi MediaTek 2x Daily ETF","start_time":0,"source_url":"","article_id":"1182838283","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182838283","pubTimestamp":1789549523,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Guizhou Bailing Group Pharmaceutical Co.,Ltd. (002424.SZ) has announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received the Drug Clinical Trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDTX":"Corgi MediaTek 2x Daily ETF","PSYK":"PSYK ETF","BK0028":"国家队","BK0239":"医药制造","BK0146":"智慧医疗","BMED":"iShares Health Innovation Active ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0183":"MSCI概念","BK0188":"融资融券","BK0077":"质押式回购","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","002424":"ST百灵"},"translate_title":"ST百灵子公司获得唐宁通络霜临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDTX":1,"BMED":1,"002424":1,"IBBJ":1,"IBBQ":1,"PSYK":1},"content_text":"Guizhou Bailing Group Pharmaceutical Co.,Ltd. (002424.SZ) has announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.The notice confirms that the clinical trial application for Tangning Tongluo Cream meets the relevant requirements for drug registration. Upon further refinement of the clinical trial protocol, approval has been granted to conduct trials for the treatment of diabetic foot ulcers.This approval marks a significant milestone in the research and development pipeline for the Tangning Tongluo series, representing a key phased achievement. It facilitates the advancement of the company's \"oral plus topical\" treatment system for diabetic complications. The receipt of clinical trial approval for the cream is not expected to have a material impact on the company's current-period financial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}